Onco360® Named National Pharmacy Partner for New Cancer and Rare Disease Treatments

Reuters

2025/06/19

Onco360® Named National Pharmacy Partner for New Cancer and Rare Disease Treatments

BrightSpring Health Services' specialty pharmacy, Onco360®, has been selected as the national pharmacy partner for several new therapies aimed at treating advanced cancers and rare genetic disorders. These therapies include treatments for advanced ovarian and lung cancers, as well as neurofibromatosis type 1. Onco360® is set to provide essential services such as access, education, and expert support for these innovative treatments. The medications approved include GOMEKLI™ for neurofibromatosis type 1, AVMAPKI™ FAKZYNJA™ CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, and IBTROZI™ for ROS1-positive non-small cell lung cancer. Jon Rousseau, President and CEO of BrightSpring, highlighted the company's commitment to delivering groundbreaking therapies to patients with serious conditions, enhancing care options and treatment alternatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightspring Health Services Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470945-en) on June 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544188622"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544188622\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544188622?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 04:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544188622","market":"fut","top_or_hot":-1,"title":"Onco360® Named National Pharmacy Partner for New Cancer and Rare Disease Treatments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Onco360® Named National Pharmacy Partner for New Cancer and Rare Disease Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BrightSpring Health Services' specialty pharmacy, Onco360®, has been selected as the national pharmacy partner for several new therapies aimed at treating advanced cancers and rare genetic disorders. These therapies include treatments for advanced ovarian and lung cancers, as well as neurofibromatosis type 1. Onco360® is set to provide essential services such as access, education, and expert support for these innovative treatments. The medications approved include GOMEKLI™ for neurofibromatosis type 1, AVMAPKI™ FAKZYNJA™ CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, and IBTROZI™ for ROS1-positive non-small cell lung cancer. Jon Rousseau, President and CEO of BrightSpring, highlighted the company's commitment to delivering groundbreaking therapies to patients with serious conditions, enhancing care options and treatment alternatives.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightspring Health Services Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470945-en) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Onco360® Named National Pharmacy Partner for New Cancer and Rare Disease Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOnco360® Named National Pharmacy Partner for New Cancer and Rare Disease Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-19 04:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Onco360® Named National Pharmacy Partner for New Cancer and Rare Disease Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BrightSpring Health Services' specialty pharmacy, Onco360®, has been selected as the national pharmacy partner for several new therapies aimed at treating advanced cancers and rare genetic disorders. These therapies include treatments for advanced ovarian and lung cancers, as well as neurofibromatosis type 1. Onco360® is set to provide essential services such as access, education, and expert support for these innovative treatments. The medications approved include GOMEKLI™ for neurofibromatosis type 1, AVMAPKI™ FAKZYNJA™ CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, and IBTROZI™ for ROS1-positive non-small cell lung cancer. Jon Rousseau, President and CEO of BrightSpring, highlighted the company's commitment to delivering groundbreaking therapies to patients with serious conditions, enhancing care options and treatment alternatives.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightspring Health Services Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470945-en) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1791807156.HKD","symbol_name":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL4ZML2L:1","article_id":"2544188622","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544188622","pubTimestamp":1750278621,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BrightSpring Health Services' specialty pharmacy, Onco360, has been selected as the national pharmacy partner for several new therapies aimed at treating advanced cancers and rare genetic disorders. These therapies include treatments for advanced ovarian and lung cancers, as well as neurofibromatosis type 1. Onco360 is set to provide essential services such as access, education, and expert support for these innovative treatments. The medications approved include GOMEKLI for neurofibromatosis type 1, AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, and IBTROZI for ROS1-positive non-small cell lung cancer. Jon Rousseau, President and CEO of BrightSpring, highlighted the company's commitment to delivering groundbreaking therapies to patients with serious conditions, enhancing care options and treatment alternatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","BK4196":"保健护理服务","LU1935043536.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (SGDHDG) INC A","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BTSG":"BrightSpring Health Services Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","KKR":"KKR & Co L.P.","LU0106831901.USD":"贝莱德世界金融基金A2","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1935043023.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (USD) INC A","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","BK4135":"资产管理与托管银行","LU1935042215.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (USD) INC A","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4588":"碎股","LU1935042488.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (USD) INC","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Onco360®被指定为癌症和罕见疾病新疗法的国家药房合作伙伴","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BTSG":0.9,"KKR":0.9,"NDAQ":0.9},"content_text":"Onco360® Named National Pharmacy Partner for New Cancer and Rare Disease Treatments\n    \n\n        BrightSpring Health Services' specialty pharmacy, Onco360®, has been selected as the national pharmacy partner for several new therapies aimed at treating advanced cancers and rare genetic disorders. These therapies include treatments for advanced ovarian and lung cancers, as well as neurofibromatosis type 1. Onco360® is set to provide essential services such as access, education, and expert support for these innovative treatments. The medications approved include GOMEKLI™ for neurofibromatosis type 1, AVMAPKI™ FAKZYNJA™ CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, and IBTROZI™ for ROS1-positive non-small cell lung cancer. Jon Rousseau, President and CEO of BrightSpring, highlighted the company's commitment to delivering groundbreaking therapies to patients with serious conditions, enhancing care options and treatment alternatives.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightspring Health Services Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470945-en) on June 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}